SEC Tracker
Get the app

Fibrogen KYNB

Armistice Capital, LLC filed a Schedule 13G/A amendment disclosing its ownership stake in FibroGen Inc. (FGEN), a biopharmaceutical company. This filing indicates Armistice Capital's continued significant investment in FibroGen, which is of interest to investors as it provides insight into the firm's strategic positioning and confidence in the company's prospects.

Ownership stake disclosure by ARMISTICE CAPITAL, LLC (amended)

Form
Schedule 13G/A
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Fibrogen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  4. Dare Bioscience DARE public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025